Skip to main content
Fig. 1 | Journal for ImmunoTherapy of Cancer

Fig. 1

From: Oncolytic adenovirus drives specific immune response generated by a poly-epitope pDNA vaccine encoding melanoma neoantigens into the tumor site

Fig. 1

In vivo pDNA and OAd combination. a Therapeutic DNA vaccination protocol in combination with oncolytic virus therapy. B16F1 cells were injected at day 0; pDNA vaccine was intramuscularly (IM) injected and electroporated 2, 9 and 16 days after tumor injection, while 109 OAd virus particles (VP) were IT injected 10, 12 and 14 days after tumor injection. Mice were sacrificed at day 17. b Evolution of tumor volume (mm3) after B16F1 challenge as a function of time (days) (mean ± SEM). All the groups were statistically compared to the others using two-way ANOVA, column factor (p < 0.05, n = 8). c-f Tumor growth measurement for the single mouse and for each group of mice. In red, mice that developed a tumor >300mm3 in volume; in green, mice with a tumor volume < 300 mm3. The a, b and c letters indicate statistical differences: the presence of two different letters in two groups indicate a statistical difference (p < 0.05) between them; the same letter in two different groups indicates the absence of a statistical difference between these two groups

Back to article page